Start Date
February 15, 2022
Primary Completion Date
November 16, 2022
Study Completion Date
November 16, 2022
HMPL-760
Administered orally QD for 28-day cycles
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Lazio
Royal Adelaide Hospital, Adelaide
Centre Antoine Lacassagne, Nice
Hôpital Saint-Antoine, Paris
Hospital del Mar, Barcelona
ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat
New York University Langone Med Center. Lab, New York
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo
Clinical Research Alliance, Westbury
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milan
Johns Hopkins Clinical Research Center, Baltimore
MD Anderson Cancer Centre, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón
Emory University Hospital, Atlanta
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna
Hospital Universitario Virgen del Rocio, Seville
Center For Advanced Medicine, St Louis
AMR Kansas City, Formerly Center for Pharmaceutical Research, an AMR company, Kansas City
Tulane Cancer Center, New Orleans
Groupe Hospitalier Pitie-Salpetriere, Paris
Oncology Consultants, P.A., Houston
Renovatio Clinical, El Paso
Renovatio Clinical, The Woodlands
CHU Poitiers - Hôpital la Milétrie, Poitiers
Innovative Clinical Research, Anaheim
Institut Gustave Roussy, Villejuif
Rabin Medical Center-Beilinson Campus, Petah Tikva
Chaim Sheba Medical Center, Ramat Gan
Tel Aviv Sourasky Medical Center, Tel Aviv
Hadassah University Hospital - Ein Kerem, Jerusalem
Summit Medical Group, Florham Park
Pratia Onkologia Katowice, Katowice
Wojewodzki Szpital Specjalistyczny w Legnicy, Legnica
Centrum Medyczne Pratia Poznan, Skórzewo
MICS Centrum Medyczne Torun, Torun
Lead Sponsor
Hutchmed
INDUSTRY